Skip to main content
Log in

Readmission common and costly after S. aureus bacteraemia

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Reference

  • Inagaki K, et al. Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus bacteremia - Nationwide Estimates of 30-day Readmission, In-hospital Mortality, Length of Stay, and Cost in the US. Clinical Infectious Diseases : 11 Feb 2019. Available from: URL: http://doi.org/10.1093/cid/ciz123

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Readmission common and costly after S. aureus bacteraemia. PharmacoEcon Outcomes News 822, 28 (2019). https://doi.org/10.1007/s40274-019-5680-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-5680-5

Navigation